Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
87.3M
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
91.4M
-
Shares change
-
+11.8M
-
Total reported value, excl. options
-
$1.07B
-
Value change
-
+$140M
-
Put/Call ratio
-
13.27
-
Number of buys
-
89
-
Number of sells
-
-53
-
Price
-
$11.71
Significant Holders of Immunome Inc. - COMMON STOCK (IMNM) as of Q3 2025
176 filings reported holding IMNM - Immunome Inc. - COMMON STOCK as of Q3 2025.
Immunome Inc. - COMMON STOCK (IMNM) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.4M shares
.
Largest 10 shareholders include FMR LLC (13.1M shares), T. Rowe Price Investment Management, Inc. (8.42M shares), BlackRock, Inc. (5.82M shares), Redmile Group, LLC (5.02M shares), VANGUARD GROUP INC (4.89M shares), Point72 Asset Management, L.P. (4.82M shares), ENAVATE SCIENCES GP, LLC (4.77M shares), EcoR1 Capital, LLC (4.08M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.74M shares), and Opaleye Management Inc. (3.19M shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.